Articles by Cecilia Brown
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
Enfortumab vedotin ranks first in efficacy among 6 treatments for metastatic urothelial cancer.
Shilpa Gupta, MD, discusses treatments for cisplatin-ineligible patients with advanced bladder cancer.
Women with advanced urothelial carcinoma have a significantly greater risk of progression after chemotherapy than men.
Lymphovascular invasion in upper tract urothelial carcinoma puts patients at higher risk for recurrence and mortality.
The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
Dr. Mary Beth Westerman, speaks on notable advances that she has see in bladder cancer throughout her career.
Dr. Westerman speaks on what clinicians can do to improve pre-operative counseling for female patients with bladder cancer.
Dr. Mary Beth Westerman provides insight on some of the main challenges in treating women with bladder cancer.
Treatment with an ICI plus a VEGF receptor inhibitor showed increased likelihood of obtaining an objective imaging response.
Failure-free survival rates between focal cryoablation and stereotactic body radiotherapy for prostate cancer no different.
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.